BioCentury | Aug 31, 2009
Company News

Endo, ProStrakan sales and marketing update

...in the EU as Tostran , Tostrex and Itnogen . It acquired the compound from Cellegy Pharmaceuticals Inc....
BioCentury | May 11, 2009
Clinical News

Fortigel testosterone regulatory update

...marketed in the EU. ProStrakan has worldwide rights to Fortigel under a 2006 deal with Cellegy Pharmaceuticals Inc....
BioCentury | Dec 8, 2008
Company News

ProStrakan, Bayer deal

...and is eligible for milestones and royalties. ProStrakan has worldwide rights to the product from Cellegy Pharmaceuticals Inc....
BioCentury | Jul 7, 2008
Finance

2H milestones

...Cell Therapeutics (NASDAQ: CTIC; Milan:CTIC)/ Bayer (Xetra:BAY) Zevalin ibritumomab Advanced follicular lymphoma Submit sBLA 2H08 Cellegy...
BioCentury | Jun 23, 2008
Clinical News

Tostran testosterone: Phase IIIb/IV data

...rights to the compound from Cellegy under a 2006 deal (see BioCentury, Oct. 2, 2006). Cellegy Pharmaceuticals Inc....
BioCentury | May 12, 2008
Finance

Ebb & Flow

...Fortify trial to treat symptoms of male hypogonadism. ProStrakan has worldwide rights to Fortigel from Cellegy...
BioCentury | May 12, 2008
Clinical News

Fortigel testosterone: Phase III data

...at day 90. ProStrakan expects to re-submit an NDA to FDA in 3Q08. In 2003, Cellegy...
...worldwide rights to Fortigel from Cellegy under a 2006 deal (see BioCentury, Oct. 2, 2006). Cellegy Pharmaceuticals Inc....
BioCentury | May 9, 2008
Clinical News

Fortigel meets hypogonadism endpoint

...re-submit an NDA to FDA for the transdermal 2% testosterone gel next quarter. In 2003, Cellegy...
...data related to chronic elevation of testosterone levels. ProStrakan has worldwide rights to Fortigel from Cellegy...
BioCentury | Apr 7, 2008
Finance

2Q milestones

...NDA Mid-08 Celgene (NASDAQ:CELG) Thalomid thalidomide Previously untreated multiple myeloma (MM) EMEA action Early 08 Cellegy...
BioCentury | Mar 17, 2008
Clinical News

Fortigel testosterone: Completed Phase III enrollment

...trial. The company licensed worldwide rights to Fortigel from Cellegy (see BioCentury, Dec. 4, 2006). Cellegy Pharmaceuticals Inc....
Items per page:
1 - 10 of 254
BioCentury | Aug 31, 2009
Company News

Endo, ProStrakan sales and marketing update

...in the EU as Tostran , Tostrex and Itnogen . It acquired the compound from Cellegy Pharmaceuticals Inc....
BioCentury | May 11, 2009
Clinical News

Fortigel testosterone regulatory update

...marketed in the EU. ProStrakan has worldwide rights to Fortigel under a 2006 deal with Cellegy Pharmaceuticals Inc....
BioCentury | Dec 8, 2008
Company News

ProStrakan, Bayer deal

...and is eligible for milestones and royalties. ProStrakan has worldwide rights to the product from Cellegy Pharmaceuticals Inc....
BioCentury | Jul 7, 2008
Finance

2H milestones

...Cell Therapeutics (NASDAQ: CTIC; Milan:CTIC)/ Bayer (Xetra:BAY) Zevalin ibritumomab Advanced follicular lymphoma Submit sBLA 2H08 Cellegy...
BioCentury | Jun 23, 2008
Clinical News

Tostran testosterone: Phase IIIb/IV data

...rights to the compound from Cellegy under a 2006 deal (see BioCentury, Oct. 2, 2006). Cellegy Pharmaceuticals Inc....
BioCentury | May 12, 2008
Finance

Ebb & Flow

...Fortify trial to treat symptoms of male hypogonadism. ProStrakan has worldwide rights to Fortigel from Cellegy...
BioCentury | May 12, 2008
Clinical News

Fortigel testosterone: Phase III data

...at day 90. ProStrakan expects to re-submit an NDA to FDA in 3Q08. In 2003, Cellegy...
...worldwide rights to Fortigel from Cellegy under a 2006 deal (see BioCentury, Oct. 2, 2006). Cellegy Pharmaceuticals Inc....
BioCentury | May 9, 2008
Clinical News

Fortigel meets hypogonadism endpoint

...re-submit an NDA to FDA for the transdermal 2% testosterone gel next quarter. In 2003, Cellegy...
...data related to chronic elevation of testosterone levels. ProStrakan has worldwide rights to Fortigel from Cellegy...
BioCentury | Apr 7, 2008
Finance

2Q milestones

...NDA Mid-08 Celgene (NASDAQ:CELG) Thalomid thalidomide Previously untreated multiple myeloma (MM) EMEA action Early 08 Cellegy...
BioCentury | Mar 17, 2008
Clinical News

Fortigel testosterone: Completed Phase III enrollment

...trial. The company licensed worldwide rights to Fortigel from Cellegy (see BioCentury, Dec. 4, 2006). Cellegy Pharmaceuticals Inc....
Items per page:
1 - 10 of 254